EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease

V Bourdin iD, Q Fossé, O Lambotte, B Joly, P Coppo iD, N Anguel, C Labeyrie

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19263 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Haematology, 2024. Verfasst von V Bourdin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hôpital Bicêtre, APHP, Université Paris Saclay, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Thrombotic Microangiopathies, Autoimmune Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life‐threatening disease that may result from drug exposure. We report a case of iTTP occurring in a 39‐year‐old patient, 45 months following introduction of the anti‐CD52 lymphoid cell depleting monoclonal antibody alemtuzumab, to treat a relapsing‐remitting multiple sclerosis. Treatment consisted in plasma exchange, corticosteroids and caplacizumab, allowing clinical remission 3 months after the diagnosis, attested by the absence of thrombocytopenia and recovery of ADAMTS‐13 activity. As other autoimmune disorders, iTTP may occur following alemtuzumab. This diagnosis should be suspected in patients with features of thrombotic microangiopathy following this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicThrombotic MicroangiopathiesAutoimmune DiseasesHumansAdultAlemtuzumabAntibodies, MonoclonalPlasma ExchangeADAMTS13 Protein

Stichwörter der Autor:innen

TTPautoimmune diseasedrug antibodies

Substanzen

AlemtuzumabAntibodies, MonoclonalADAMTS13 Protein

Autor:innen und Institutionen

  • Internal Medicine Department, Hôpital Bicêtre, APHP, Université Paris Saclay, Le Kremlin-Bicêtre, France.
  • AP-HP, Intensive Care Unit, Hôpital Bicêtre, DMU CORREVE, Inserm UMR S_999, FHU SEPSIS, Groupe de Recherche Clinique CARMAS, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Université Paris Saclay, Inserm, CEA, UMR 1184 ImVA-HB, Le Kremlin Bicêtre, France.
  • Biologic Hematology Department, Hopital Lariboisière and EA3518, Institut de Recherche Saint-Louis, APHP.Nord, Université Paris-Cité, Paris, France.
  • French Reference Center for Thrombotic Microangiopathies (CNR-MAT), Saint Antoine University Hospital, APHP, Sorbonne University, Paris, France.
  • Hematology Department, Hopital Saint-Antoine, APHP, Sorbonne University, Paris, France.

ORCID-Profile: V Bourdin, P Coppo

Zitieren

APA

Bourdin, V., Fossé, Q., Lambotte, O., Joly, B., Coppo, P., Anguel, N., & Labeyrie, C. (2024). Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease. British Journal of Haematology. https://doi.org/10.1111/bjh.19263

Vancouver

Bourdin V, Fossé Q, Lambotte O, Joly B, Coppo P, Anguel N, et al. Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease. British Journal of Haematology. 2024. doi:10.1111/bjh.19263

BibTeX
@article{Bourdin2024,
  author = {Bourdin, V and Fossé, Q and Lambotte, O and Joly, B and Coppo, P and Anguel, N and Labeyrie, C},
  title = {Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19263}
}
Kostenlos starten →